Cargando…
Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition
The notable unbiased of this research work was to evaluate the well-being and effectiveness of metaxalone by administering the newly developed test and reference drug. A two-period, two-categorization, crossover bioavailability study in fed conditions. Eleven participants were dosed and completed th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022370/ https://www.ncbi.nlm.nih.gov/pubmed/35464658 http://dx.doi.org/10.4103/japtr.japtr_362_21 |
_version_ | 1784690068039925760 |
---|---|
author | Colaco, Socorrina Ramesh, N. Shabaraya, Ramakrishna |
author_facet | Colaco, Socorrina Ramesh, N. Shabaraya, Ramakrishna |
author_sort | Colaco, Socorrina |
collection | PubMed |
description | The notable unbiased of this research work was to evaluate the well-being and effectiveness of metaxalone by administering the newly developed test and reference drug. A two-period, two-categorization, crossover bioavailability study in fed conditions. Eleven participants were dosed and completed the trial successfully. The drugs were administered by way of a schedule. Samples collected in both periods for pharmacokinetic evaluation. Plasma samples analyzed using a validated method. Pharmacokinetic parameters for investigational and reference products were calculated using the metaxalone drug concentration and safety of the participants monitored by measurement of vital sign. Relative estimation factors calculated for Cmax, Tmax, area under the curve (AUC) t, AUC inf, K el, half-life, and 90% confidence intervals applied for to check for whether reference and test products are equivalent. The experimental part of the study was completed with no major adversarial event. No losses or stern adverse events transpired throughout the course of the experiment. The assessment product is analogous to reference product in relation to degree and extent of absorption. The outcome of this study indicates the newly developed drug is equivalent to the innovator drug and medication was well tolerated by all participants. |
format | Online Article Text |
id | pubmed-9022370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-90223702022-04-22 Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition Colaco, Socorrina Ramesh, N. Shabaraya, Ramakrishna J Adv Pharm Technol Res Original Article The notable unbiased of this research work was to evaluate the well-being and effectiveness of metaxalone by administering the newly developed test and reference drug. A two-period, two-categorization, crossover bioavailability study in fed conditions. Eleven participants were dosed and completed the trial successfully. The drugs were administered by way of a schedule. Samples collected in both periods for pharmacokinetic evaluation. Plasma samples analyzed using a validated method. Pharmacokinetic parameters for investigational and reference products were calculated using the metaxalone drug concentration and safety of the participants monitored by measurement of vital sign. Relative estimation factors calculated for Cmax, Tmax, area under the curve (AUC) t, AUC inf, K el, half-life, and 90% confidence intervals applied for to check for whether reference and test products are equivalent. The experimental part of the study was completed with no major adversarial event. No losses or stern adverse events transpired throughout the course of the experiment. The assessment product is analogous to reference product in relation to degree and extent of absorption. The outcome of this study indicates the newly developed drug is equivalent to the innovator drug and medication was well tolerated by all participants. Wolters Kluwer - Medknow 2022 2022-04-07 /pmc/articles/PMC9022370/ /pubmed/35464658 http://dx.doi.org/10.4103/japtr.japtr_362_21 Text en Copyright: © 2022 Journal of Advanced Pharmaceutical Technology & Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Colaco, Socorrina Ramesh, N. Shabaraya, Ramakrishna Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition |
title | Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition |
title_full | Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition |
title_fullStr | Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition |
title_full_unstemmed | Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition |
title_short | Demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition |
title_sort | demonstration of relative bioavailability of newly developed and innovator drug metaxalone 800 mg in healthy subjects under fed condition |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022370/ https://www.ncbi.nlm.nih.gov/pubmed/35464658 http://dx.doi.org/10.4103/japtr.japtr_362_21 |
work_keys_str_mv | AT colacosocorrina demonstrationofrelativebioavailabilityofnewlydevelopedandinnovatordrugmetaxalone800mginhealthysubjectsunderfedcondition AT rameshn demonstrationofrelativebioavailabilityofnewlydevelopedandinnovatordrugmetaxalone800mginhealthysubjectsunderfedcondition AT shabarayaramakrishna demonstrationofrelativebioavailabilityofnewlydevelopedandinnovatordrugmetaxalone800mginhealthysubjectsunderfedcondition |